(Breast Cancer) Taiho Submits Additional Application for TS-1 as Adjuvant Chemotherapy

• February 22, 2022
• 1 min read

On February 14, 2022, Taiho Pharmaceutical Co., Ltd. submitted an additional application to Japan's Ministry of Health, Labour and Welfare (MHLW) for the oral anticancer drug TS-1 as adjuvant chemotherapy following breast cancer surgery.

Approximately 95,000 new female cancer cases are diagnosed annually in Japan, of which approximately 75% are hormone receptor (HR)-positive and HER2-negative breast cancer. Standard post-surgical treatment for early-stage patients includes drug therapy and post-operative endocrine therapy in addition to surgery.

This application is based on results from the POTENT Phase 3 clinical trial, which demonstrated that 1 year of TS-1 combined with 5 years of endocrine therapy effectively suppressed disease recurrence in HR+, HER2-negative breast cancer patients. Compared to the control arm, invasive disease-free survival (IDFS) was significantly extended, and the safety profile was consistent with existing safety data.

Furthermore, this combination regimen received MHLW approval in March 2011 as post-operative therapy for HR+, HER2-negative breast cancer patients, classified under Advanced Medical Care Category B.

Taiho Pharmaceutical stated its commitment to obtaining approval to provide breast cancer patients with a new treatment option.

Source: https://www.taiho.co.jp/release/2022/20220214.html

• Clinical Trial Medications

  • (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
  • (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
  • (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4